« Return to News | Awards & Advancement

MEI Pharma appoints Nick Glover to board of directors

Friday, June 14, 2013 01:35 PM

MEI Pharma, an oncology company focused on the clinical development of novel therapies for cancer, has appointed Nick Glover, Ph.D., to its board of directors, increasing the board to seven members, including six independent directors.

"In addition to firsthand experience leading an emerging hematology drug development company, Nick has an extensive background in business development and strong relationships within the life science investment community,” said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. “We look forward to the benefit of his experience as we execute multiple phase II clinical trials of Pracinostat in the months ahead and formulate strategies for maximizing its value."

Glover served as president and chief executive officer of YM BioSciences from November 2010 until the completion of its acquisition by Gilead in February 2013. Glover also was president and chief executive officer of Viventia Biotech, involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer, and previously he was an investment manager at MDS Capital, a life sciences venture capital firm.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.